Core Viewpoint - WuXi Biologics (02269) experienced a 2.09% decline in stock price, trading at 29.1 HKD per share with a transaction volume of 3.59 billion HKD as of 10:29 AM on August 12 [1] Company Overview - WuXi Biologics is a leading global provider of biologics services, offering comprehensive, integrated, and highly customized services throughout the entire process from discovery and development to production of biologics [1] - The company held a 48% market share in China's biologics R&D market in 2016 and has established partnerships with 12 out of the top 20 global pharmaceutical companies [1] Financial Performance - As of the 2024 annual report, WuXi Biologics reported total revenue of 18.675 billion RMB and a net profit of 3.356 billion RMB [1] - The company is set to disclose its interim report for the fiscal year 2025 on August 19 [1]
药明生物(02269)下跌2.09%，报29.1元/股